News Sentiment

ANTX sentiment intelligence

AN2 Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.50 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+1.8% over one week, -5.1% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Price to book forward of AN2 Therapeutics, Inc. – NASDAQ:ANTX

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 1.8% Price digesting
Trend fit Trend active -5.1% over four weeks
Fair value -1.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 32
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingView 7
Market source 5
Business Wire 3
simplywall.st 3
Investing.com 2
dars.gov.et 2
www.marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 16
Balance sheet 4
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-47 of 47
Stock Titan Direct company coverage

Biotech CEO Eric Easom to speak at Jefferies Global Healthcare Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced that its Co-Founder, Chairman, President, and CEO, Eric Easom, will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM ET. The company, a clinical-stage biopharmaceutical firm focusing on novel s

Tone
Positive 61/100
Event
Market update
Published
21 May 2026 11:08
Source
Stock Titan
Stock Titan Direct company coverage

Almitas Capital holds 4.1% of AN2 Therapeutics (NASDAQ: ANTX)

Almitas Capital LLC has reported a beneficial ownership of 1,479,129 shares in AN2 Therapeutics (NASDAQ: ANTX), representing a 4.1% stake in the company. This disclosure was made via an amended Schedule 13G/A filing, signed by Ronald Mass on May 15, 2026. Almitas Capital holds so

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 May 2026 01:40
Source
Stock Titan
Zacks Investment Research Direct company coverage

Should I buy AN2 Therapeutics (ANTX)

Tone
Positive 66/100
Event
Market update
Published
09 Jan 2026 08:00
Source
Zacks Investment Research